Portuguese Tennis player Silva Receives One-Month Suspension Following Trimétazidine Positive Test
September 25, 2025 – Frederico Ferreira Silva, a 30-year-old Portuguese tennis player, has accepted a one-month suspension from the International Tennis Integrity agency (ITIA) after testing positive for the prohibited substance trimétazidine (TMZ) during a competition in February 2025. The ITIA confirmed the violation but resolute the positive test resulted from contamination of a regulated prescription medication and was not intentional.
The ITIA investigation, supported by laboratory analysis from lama confirming the presence of TMZ in Silva’s medication, a verification by an self-reliant expert from the ITIA (l’itia), and documentation from the dispensing pharmacy, led to the lifting of a provisional suspension.
According to the ITIA, Silva’s level of fault was deemed “very low” due to the contaminated product – DAFLON 1000 mg – being a legally prescribed drug issued by a sports medicine specialist and purchased through his national tennis federation following medical consultation.
Having already served a period of ineligibility exceeding the standard duration for a provisional suspension during the investigation, Silva is now eligible to resume play.
Trimétazidine is a metabolic agent prohibited under the World Anti-Doping code.While frequently enough prescribed for angina, its use in sports is banned due to potential performance-enhancing effects. This case highlights the complexities of anti-doping regulations and the potential for inadvertent violations through contaminated supplements or medications.
(Note: The Twitter embed code was omitted as it’s not necessary for the rewritten article and can cause rendering issues in some contexts.)
